Vaccination against avian influenza (AI) is currently applied worldwide with inactivated vaccines. Since November 2012 , a novel recombinant rHVT-AIH 5 (Herpesvirus of turkeys as vector) vaccine has been commercialized and applied to day-old chicks (DOC) in some industrial hatcheries in Egypt (Kilany , 2014 ; Kilany , 2012). The objectives of this study were to assess the cost-effectiveness of AI DOC vaccination in hatcheries and the feasibility of implementing AI DOC vaccination in the different production sectors in Egypt. A model of the Egyptian poultry production network was combined with a model on flock immunity to simulate the distribution profile of AI immunity according to different vaccination scenarios (including DOC vaccination or not). The model estimated the levels of vaccine coverage for each node of the network and vaccination scenario and positive sero-conversion levels and the duration of sero-protection. The model predicted that targeting DOC AI vaccination in industrial and large size hatcheries would increase immunity levels in the overall poultry population in Egypt and especially in small commercial poultry farms (from < 30 % to > 60 %). This strategy was shown to be more efficient than the current strategy using inactivated vaccines. Improving HPAI control in the commercial poultry sector in Egypt would have a positive impact effect to improve disease control. This innovative way to analyze the outcome of AI immunity predictive model supports the design of a more efficient HPAI disease control plan in Egypt. This model may be replicated in other AIV endemic countries that wish to better manage infections or emerging disease threats.